Tempus AI (NASDAQ:TEM) sits at the intersection of artificial intelligence, genomics, oncology, and drug development. That combination has created a compelling growth story, especially as the company expands artificial intelligence tools and biopharma partnerships. The stock’s challenge is simple: growth is impressive, but Wall Street still needs proof that the model can scale profitably.
Stock prices used were the market prices of June 1, 2026. The video was published on June 7, 2026. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this video.
